Arie Belldegrun
Overview
Explore the profile of Arie Belldegrun including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
1505
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lebacle C, Pooli A, Shuch B, Rao N, Chamie K, Kroeger N, et al.
Cancer Invest
. 2024 Feb;
42(1):97-103.
PMID: 38314786
Approximately 65% of renal cell carcinomas (RCC) are diagnosed at a localized stage. We investigated the chromosome 5q gain impact on disease-free survival (DFS) in RCC patients. Overall, 676 patients...
2.
Young J, Coy H, Kim H, Douek M, Sisk A, Belldegrun A, et al.
Abdom Radiol (NY)
. 2018 Mar;
43(10):2734-2742.
PMID: 29520426
Purpose: To investigate if multiphasic multidetector computed tomography (MDCT) enhancement profiles can distinguish clear cell renal cell carcinomas (ccRCCs) with high carbonic anhydrase-IX (CA-IX) expression from ccRCCs with low CA-IX...
3.
Lenis A, Donin N, Faiena I, Salmasi A, Johnson D, Drakaki A, et al.
Urol Oncol
. 2017 Oct;
36(1):9.e1-9.e9.
PMID: 29066013
Objectives: With increasing utilization of robot-assisted surgery in urologic oncology, robotic nephroureterectomy (RNU) is becoming the surgical modality of choice for patients with upper tract urothelial carcinoma (UTUC). The role...
4.
Wei X, Choudhury Y, Lim W, Anema J, Kahnoski R, Lane B, et al.
Sci Rep
. 2017 Aug;
7(1):7342.
PMID: 28779136
Clear cell renal cell carcinoma (ccRCC) has been previously classified into putative discrete prognostic subtypes by gene expression profiling. To investigate the robustness of these proposed subtype classifications, we evaluated...
5.
Adjuvant Therapy for High Risk Localized Kidney Cancer: Emerging Evidence and Future Clinical Trials
Lenis A, Donin N, Johnson D, Faiena I, Salmasi A, Drakaki A, et al.
J Urol
. 2017 May;
199(1):43-52.
PMID: 28479237
Purpose: We reviewed the literature on adjuvant therapies for patients with high risk localized kidney cancer following surgical resection. In this analysis we merge 2 recently published prospective trials with...
6.
Donin N, Lenis A, Holden S, Drakaki A, Pantuck A, Belldegrun A, et al.
J Urol
. 2016 Jul;
197(1):14-22.
PMID: 27460757
Purpose: We review the biological mechanisms of action, clinical safety and efficacy of immunotherapies for urothelial carcinoma. We also describe current areas of research in immunotherapy, and highlight ongoing trials...
7.
8.
Oosterwijk E, Rathmell W, Junker K, Brannon A, Pouliot F, Finley D, et al.
Eur Urol
. 2011 Jul;
60(4):622-33.
PMID: 21741760
Context: Advances in basic research will enhance prognosis, diagnosis, and treatment of renal cancer patients. Objective: To discuss advances in our understanding of the molecular basis of renal cancer, targeted...
9.
Molina A, Belldegrun A
J Urol
. 2011 Jan;
185(3):787-94.
PMID: 21239012
Purpose: Androgen receptor signaling remains essential for many prostate cancers that have progressed despite androgen deprivation therapy. After medical or surgical castration persistent though not insignificant low levels of androgens...
10.
La Rochelle J, Klatte T, Dastane A, Rao N, Seligson D, Said J, et al.
Cancer
. 2010 Jul;
116(20):4696-702.
PMID: 20629029
Background: The authors investigated whether deletion of chromosome 9p in clear cell renal cell carcinoma (ccRCC) predicted worse disease-specific survival (DSS) and recurrence-free survival (RFS) and whether it was associated...